Expression levels of the EMT marker c-MET, cancer stemness markers ABCG2 and CD133a, which is both HH-GLI target and cancer stemness marker, were significantly decreased in the combined treatment of 5-FU and ATO (Figure 4B). Here, MET is linked to cancer.